Biotechnology
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)
TAIPEI, Nov. 9, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercial...
2020-11-09 18:22
1795
Termination of Bridge Biotherapeutics's Collaboration and License Agreement with Boehringer Ingelheim
SEONGNAM, South Korea, Nov. 9, 2020 /PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into inJuly 2019 to...
2020-11-09 18:07
1488
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
NEW YORK, Nov. 5, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in ...
2020-11-05 21:00
974
Gracell Biotechnologies Announces Two Oral Presentations at the ASH Annual Meeting and Exposition 2020
SUZHOU and SHANGHAI, China, Nov. 4, 2020 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced two oral presentations at the...
2020-11-05 11:52
1353
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digi...
2020-11-04 20:00
1760
Great Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%
HONG KONG, Nov. 2, 2020 /PRNewswire/ -- Klone 4.0 accomplishes both in a manner that could potentially disrupt the bioprocessing industry, firstly by reducing development times by up to 80% as AI eliminates many of the laboratory pain points through GBB's proprietary deep machine learning techniq...
2020-11-02 22:00
1300
Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc.
(TPEx: 6492), a clinical-stage biopharmaceutical company focused on
next-generation DNA Damage Response (DDR) therapeutics for the treatment of
cancer, today announced that it has submitted an Investigational New Drug
2020-11-02 22:00
1741
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
SHANGHAI, Nov. 2, 2020 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited ("CARsgen"), a leading biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, today announced the completion of aUSD 186 million Series C Equity Financing. The...
2020-11-02 19:00
3608
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
INCHEON, South Korea and SUZHOU, China, Nov. 1, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma ...
2020-11-02 08:27
1398
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000
TAIPEI, Taiwan, Nov. 1, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") (Taiwan: 4157) announced today that U.S. Food and Drug Administration ("FDA") has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B. TG-1000 is a...
2020-11-02 07:30
1279
Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatme...
2020-10-29 20:00
7379
Samsung Biologics expands global footprint with opening of new San Francisco CDO R&D Center
INCHEON, South Korea and SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- At a virtual ceremony today, Samsung Biologics (KRX: 207940.KS) announced the grand opening of its first US CDO R&D Center inSan Francisco, bringing its contract development services closer to global clients. As the "Next Door ...
2020-10-29 08:38
6607
Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies
SHANGHAI and SUZHOU, China, Oct. 28, 2020 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced it has secured$100 million i...
2020-10-28 21:00
2032
Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab
* The first microbiome oncology therapeutic candidate developed by an Asia -based biotech successfully initiatesphase 1/1b clinical trial in the US, six months after its IND went into effect. * The first patient enrolled and treated at OHSU (Oregon Health & Science University Knight Cancer In...
2020-10-27 21:00
1408
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company will present the latest preclinical dat...
2020-10-27 20:05
4617
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...
2020-10-27 10:03
3599
Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis
* SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance * Both doses were shown to be superior to placebo for key secondary endpoints * AEs were manageable and generally transient and r...
2020-10-26 19:40
1428
PharmAbcine to participate at BIO-Europe 2020
DAEJEON, South Korea, Oct. 23, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will participate in the 26th Annual International BIO-Europe Partnering Conference which will be held digitally from October 26th to 29th. PharmAbcine's business development ...
2020-10-23 20:00
10383
Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement
SHANGHAI, Oct. 22, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced that it has signed a definitive merger agreement with 4D pharma PLC (AIM: DDDD, "4D pharma" or "4D"). Upon co...
2020-10-22 14:00
9267
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...
2020-10-21 19:00
8171
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 312 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8700
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5793
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5179
